The addition of blinatumomab after induction chemotherapy in children with standard-risk disease of average or high risk of relapse significantly improved disease-free survival.
The New England Journal of Medicine: Search Results in Pediatrics
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
